Is metformin still the first choice for PCOS in 2026?

Yes, according to all major international guidelines (ESHRE 2023, NICE 2023, Endocrine Society 2023). Metformin remains recommended as first-line therapy for women with PCOS and documented insulin resistance, due to its favorable benefit-risk ratio, very low cost ($4–15/month generic), and 60 years of safety data. GLP-1 agonists are considered second-line if metformin response is insufficient, or first-line when significant weight loss is the priority in patients with BMI ≥ 30.

Ozempic or Mounjaro for PCOS: which one to choose?

Tirzepatide (Mounjaro) has since 2024 the SURMOUNT-PCOS trial (NEJM), specifically designed for PCOS: 65% return to regular cycles vs 22% under placebo, weight loss averaging -15.4%. Semaglutide (Ozempic/Wegovy) has fewer PCOS-specific data but well-documented efficacy on weight (10–15%) and a longer safety track record. Neither is FDA-approved for PCOS; both are off-label. Choice should be made with an endocrinologist based on clinical profile and insurance/cost considerations.

Can metformin help with weight loss in PCOS?

Metformin produces modest weight loss in PCOS: an average of 4 to 9 lbs (2 to 4 kg) over 6 months in clinical studies, compared to 10 to 22% of body weight with GLP-1 agonists. This weight effect from metformin comes from reducing hyperinsulinemia (less fat storage) and a mild appetite reduction. It is not recommended as a weight-loss drug alone. If weight loss is the primary goal, GLP-1 agonists are substantially more effective.

Can metformin and GLP-1 be combined for PCOS?

Yes, and this combination shows additive benefit in several studies. Metformin and GLP-1 agonists act at different levels of the insulin resistance cascade (hepatic/systemic for metformin; hypothalamic/pancreatic/ovarian for GLP-1 agonists). In SURMOUNT-PCOS, approximately 40% of participants continued metformin alongside tirzepatide. In practice, many physicians maintain metformin when initiating a GLP-1 agonist, particularly for its additional hepatic metabolic benefit.

Are GLP-1 agonists covered by insurance for PCOS in the US?

Not for PCOS specifically. GLP-1 agonists are not FDA-approved for PCOS. Insurance coverage varies: semaglutide (Ozempic) is often covered for type 2 diabetes (if diagnosed with PCOS + T2DM); Wegovy is sometimes covered for obesity (BMI ≥ 30 or ≥ 27 with comorbidity). Prior authorization is almost always required, and many plans have excluded GLP-1 obesity coverage due to cost. Without insurance, Wegovy costs $500–850/month, Mounjaro $500–800/month. GoodRx and manufacturer coupons can reduce costs significantly.

What are the side effects of metformin for PCOS?

Gastrointestinal side effects (nausea, diarrhea, abdominal cramps, metallic taste) affect 20 to 30% of patients at initiation and are dose-dependent. They usually improve after 4 to 8 weeks. Extended-release metformin (metformin ER/XR) substantially reduces GI side effects and improves adherence. Long-term: vitamin B12 deficiency (10 to 30% of long-term users — check annually). Metformin does not cause hypoglycemia on its own.

Does metformin improve fertility in PCOS?

Yes, with Grade B evidence. Metformin improves ovulation rate and can restore regular cycles in women with PCOS and insulin resistance. Used alone or in combination with clomiphene citrate, it improves pregnancy rates. ESHRE 2023 recommends metformin as an adjunct to ovulation induction. However, evidence is insufficient to recommend it universally in all women with PCOS seeking conception, particularly in the absence of documented insulin resistance.

Should metformin be stopped during pregnancy with PCOS?

Current practice varies. Available data (including the MiG trial — Metformin in Gestational Diabetes) do not show increased congenital malformations at therapeutic doses. However, metformin crosses the placenta and long-term data on children exposed in utero remain limited. The general approach in the US is to discontinue metformin in the first trimester unless gestational diabetes or type 2 diabetes requires its continuation. Always discuss with your OB or endocrinologist before making any change during pregnancy.

Evidence review · updated 18 May 2026

Metformin vs GLP-1 for PCOS / PMOS: Should You Switch in 2026?

Metformin has 60 years of evidence in PCOS. GLP-1 agonists lose more weight and restore cycles in 65% of women vs ~50% for metformin. But at $500–800/month with no FDA approval for PCOS, the question isn't which is better — it's which is right for you.

Information, not a diagnosis. This page provides general guidance. It does not constitute a diagnosis and does not replace a personalised medical consultation.

Quick Verdict

Metformin: recommended first-line by all 2023 guidelines. 60 years of data, ~$10/month generic, improves insulin resistance and cycles, supports fertility (Grade B evidence). The metabolic foundation of PCOS treatment.
GLP-1 agonists (Ozempic, Mounjaro…): substantially superior for weight loss (-15 to -22% vs 4–9 lbs), better cycle restoration (65% vs ~50% with metformin alone). But off-label for PCOS, rarely covered by insurance, $500–800/month.
Combining both: documented additive benefit — recommended approach if metformin response is insufficient and cost is manageable.
Should you switch in 2026? No — replacing metformin with a GLP-1 is not warranted. Adding a GLP-1 if BMI ≥ 30 and weight loss goal unmet is the evidence-based step.

How each drug works in PCOS / PMOS

PCOS/PMOS is fundamentally a syndrome of insulin resistance in 50 to 70% of patients. This insulin resistance generates compensatory hyperinsulinemia that stimulates ovarian theca cells and drives excess androgen production. The central causal chain: insulin resistance → hyperinsulinemia → hyperandrogenism → ovulatory dysfunction. Both metformin and GLP-1 agonists act on this mechanism — but at different levels.

Metformin — 60 years of clinical experience

Metformin (biguanide) acts primarily by inhibiting hepatic gluconeogenesis via AMPK (AMP-activated protein kinase) activation. Concretely: it reduces glucose production by the liver and improves insulin sensitivity in muscle and adipose tissue, which decreases hyperinsulinemia. In PCOS, this reduces insulin-driven stimulation of ovarian theca cells, lowers ovarian androgen production (testosterone, androstenedione), and progressively improves ovulatory function.

Metformin also favorably modifies the gut microbiome, an increasingly recognized contributor to its systemic metabolic effects (Forslund et al., Nature 2017). It produces modest appetite reduction, contributing to mild weight loss (4–9 lbs on average). It does not cause hypoglycemia in isolation because it does not directly stimulate insulin secretion.

GLP-1 agonists — multiple mechanisms, ovarian effects included

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — activate receptors broadly distributed in the body: pancreatic beta cells, hypothalamus, vagus nerve, and — crucially for PCOS — ovarian granulosa cells. This distribution explains their multiple effects:

Pancreas: stimulates insulin secretion in a glucose-dependent manner (no hypoglycemia if blood glucose is normal) + inhibits glucagon.
Hypothalamus/brain: powerful appetite reduction, reduced cravings, and decreased drive for high-calorie foods.
Stomach: slows gastric emptying → prolonged satiety.
Ovaries: GLP-1 receptors on granulosa cells respond directly to activation — improvement in follicular development and oocyte quality. This direct ovarian effect, absent with metformin, partly explains why GLP-1 agonists show better ovulation restoration in PCOS even at equivalent weight loss.

Level of action	Metformin	GLP-1 agonist
Liver	Inhibits gluconeogenesis (AMPK) +++	Weak direct effect
Muscle/adipose tissue	Insulin sensitivity ++	Insulin sensitivity ++ (indirect)
Pancreas	No secretory effect	Glucose-dependent insulin stimulation +++
Hypothalamus/appetite	Mild effect	Powerful appetite suppression +++ (central action)
Stomach	None	Slows gastric emptying ++
Ovaries (granulosa cells)	No direct effect	Direct effect via GLP-1 receptor +
Gut microbiome	Favorable modification ++	Modification (preliminary data)

Clinical evidence

Metformin in PCOS — the foundational data

Metformin has a high level of evidence in PCOS, accumulated over several decades:

NICE 2023: recommends metformin as first-line treatment for insulin resistance in PCOS, particularly in women with BMI ≥ 25 and HOMA-IR > 2.5.
ESHRE 2023: recommends metformin for metabolic and ovulatory outcomes in PCOS. Grade B recommendation. Specific mention that metformin improves cycle regularity in ~50% of women with PCOS and insulin resistance.
Nestler JE et al. (NEJM 1996): foundational study showing that metformin reduces hyperinsulinemia in PCOS and improves ovulation.
Tang T et al. (BMJ 2012): meta-analysis of 44 RCTs (n = 3,476 women with PCOS). Metformin significantly improves cycle regularity (OR = 2.76), ovulation rate, and metabolic parameters versus placebo.

GLP-1 agonists in PCOS — the emerging evidence

GLP-1 data in PCOS has grown substantially since 2022. The current reference trial is SURMOUNT-PCOS (NEJM 2024):

Tirzepatide 10–15 mg vs placebo over 32 weeks (n = 326 women with PCOS and obesity)
Return to regular cycles: 65% (tirzepatide) vs 22% (placebo)
Weight loss: -15.4% (15 mg) vs -2.1% (placebo)
Free testosterone: -38% vs -8%
HOMA-IR: -52% vs -12%

For semaglutide, PCOS-specific data come primarily from STEP trial subgroups (Wilding et al., NEJM 2021) and observational studies: cycle improvement in 40 to 45% of women, weight loss 10 to 15%, free testosterone reduction 20 to 25%.

Metformin + GLP-1 combined — additive benefit

Several studies and subgroup analyses support an additive benefit of combining metformin + GLP-1 agonists. The biological rationale is solid: the two agents act at distinct levels of the insulin resistance cascade (hepatic/systemic for metformin; hypothalamic/pancreatic/ovarian for GLP-1 agonists). In SURMOUNT-PCOS, patients who continued metformin alongside tirzepatide showed slightly superior HOMA-IR improvements. ESHRE 2023 mentions the combination as an option in severe insulin resistance cases.

Full comparison table — metformin vs GLP-1

Criterion	Metformin	GLP-1 agonist
Clinical track record	60 years (since 1957)	5–15 years depending on molecule
Average weight loss	-4–9 lbs over 6 months	-15 to -22% body weight (Mounjaro, SURMOUNT-PCOS)
Cycle restoration	~50% (RCTs, ESHRE 2023)	65% (tirzepatide, SURMOUNT-PCOS NEJM 2024)
Monthly cost (US)	$4–15 (generic)	$500–850 (Ozempic/Wegovy/Mounjaro) without insurance
Side effects	GI effects (20–30%); B12 deficiency long-term	Nausea/vomiting (30–50%) transitional; rare pancreatitis
Prescription	Primary care physician	Specialist recommended (off-label for PCOS)
Insurance coverage (PCOS)	Often covered if insulin resistance documented	Not covered for PCOS; sometimes for obesity/T2DM
Route of administration	Oral tablets	Weekly SC injection (or daily for liraglutide)
Contraindicated in pregnancy	No (data generally reassuring)	Yes — must stop before conception
FDA approval for PCOS	No (off-label)	No (off-label)

Which treatment for your profile?

Profile 1 — PCOS with moderate insulin resistance, normal or slightly elevated BMI (25–29)

Metformin is the first choice. Starting dose: 500 mg/day with dinner, progressive increase over 4 to 6 weeks to 1,500–2,000 mg/day in two doses. Reassess at 3 months (menstrual cycles, HOMA-IR). Extended-release metformin (ER/XR) significantly improves GI tolerability.

Profile 2 — PCOS with obesity (BMI ≥ 30) and weight loss as a priority goal

GLP-1 agonists are the most effective option. Tirzepatide (Mounjaro) has the best data specifically in PCOS (SURMOUNT-PCOS). Semaglutide (Wegovy) is an alternative with a longer safety track record. Metformin can be maintained in combination for its additional hepatic benefit. Cost to anticipate: $500–850/month without insurance. Prior discussion with an endocrinologist is essential.

Profile 3 — PCOS with concurrent type 2 diabetes

Metformin remains the foundation (recommended first-line for type 2 diabetes by all international guidelines). A GLP-1 agonist can be added as second-line therapy based on HbA1c and glycemic goals — in this case, the GLP-1 prescription falls within the FDA-approved type 2 diabetes indication, improving insurance coverage.

Profile 4 — PCOS with plans for pregnancy in the near term (6–12 months)

Metformin is preferred because GLP-1 agonists are formally contraindicated during pregnancy and require a washout period (2 months for semaglutide, 1 month for tirzepatide) before any conception attempt. Metformin improves ovulation and supports conception attempts with an acceptable safety profile in early pregnancy based on current data.

Profile 5 — PCOS with insufficient response to metformin after 6 months

First reassess adherence (correct dose? ER formulation tried?) and lifestyle factors. If response is genuinely insufficient (persistently irregular cycles, HOMA-IR > 3 maintained), discuss therapeutic escalation: adding inositol (see inositol vs metformin), then a GLP-1 agonist if BMI ≥ 27 and budget/insurance allows.

Safety notes

GLP-1 agonists — Pregnancy contraindication (critical)

Formally contraindicated during pregnancy and breastfeeding
Semaglutide: stop at least 2 months before any conception attempt (long half-life)
Tirzepatide: stop at least 1 month before conception
Contraception mandatory during treatment — improved ovulation can come as a surprise
Pancreatitis warning: upper abdominal pain radiating to the back → stop immediately and seek care
Thyroid medullary carcinoma / MEN 2: absolute contraindication for all GLP-1 agonists

Metformin — Monitoring points

Annual vitamin B12 monitoring if on long-term therapy
Check kidney function (eGFR) before starting and periodically; contraindicated if eGFR < 30
Hold metformin 48 h before and after contrast dye procedures (CT with contrast)
Extended-release (ER/XR) formulation significantly reduces GI side effects

Frequently asked questions

Is metformin still the first choice for PCOS in 2026?: Yes, according to all major international guidelines (ESHRE 2023, NICE 2023, Endocrine Society 2023). Metformin remains recommended as first-line therapy for women with PCOS and documented insulin resistance, due to its favorable benefit-risk ratio, very low cost ($4–15/month generic), and 60 years of safety data. GLP-1 agonists are considered second-line if metformin response is insufficient, or first-line when significant weight loss is the priority in patients with BMI ≥ 30.
Ozempic or Mounjaro for PCOS: which one to choose?: Tirzepatide (Mounjaro) has since 2024 the SURMOUNT-PCOS trial (NEJM), specifically designed for PCOS: 65% return to regular cycles vs 22% under placebo, weight loss averaging -15.4%. Semaglutide (Ozempic/Wegovy) has fewer PCOS-specific data but well-documented efficacy on weight (10–15%) and a longer safety track record. Neither is FDA-approved for PCOS; both are off-label. Choice should be made with an endocrinologist based on clinical profile and insurance/cost considerations.
Can metformin help with weight loss in PCOS?: Metformin produces modest weight loss in PCOS: an average of 4 to 9 lbs (2 to 4 kg) over 6 months in clinical studies, compared to 10 to 22% of body weight with GLP-1 agonists. This weight effect from metformin comes from reducing hyperinsulinemia (less fat storage) and a mild appetite reduction. It is not recommended as a weight-loss drug alone. If weight loss is the primary goal, GLP-1 agonists are substantially more effective.
Can metformin and GLP-1 be combined for PCOS?: Yes, and this combination shows additive benefit in several studies. Metformin and GLP-1 agonists act at different levels of the insulin resistance cascade (hepatic/systemic for metformin; hypothalamic/pancreatic/ovarian for GLP-1 agonists). In SURMOUNT-PCOS, approximately 40% of participants continued metformin alongside tirzepatide. In practice, many physicians maintain metformin when initiating a GLP-1 agonist, particularly for its additional hepatic metabolic benefit.
Are GLP-1 agonists covered by insurance for PCOS in the US?: Not for PCOS specifically. GLP-1 agonists are not FDA-approved for PCOS. Insurance coverage varies: semaglutide (Ozempic) is often covered for type 2 diabetes (if diagnosed with PCOS + T2DM); Wegovy is sometimes covered for obesity (BMI ≥ 30 or ≥ 27 with comorbidity). Prior authorization is almost always required, and many plans have excluded GLP-1 obesity coverage due to cost. Without insurance, Wegovy costs $500–850/month, Mounjaro $500–800/month. GoodRx and manufacturer coupons can reduce costs significantly.
What are the side effects of metformin for PCOS?: Gastrointestinal side effects (nausea, diarrhea, abdominal cramps, metallic taste) affect 20 to 30% of patients at initiation and are dose-dependent. They usually improve after 4 to 8 weeks. Extended-release metformin (metformin ER/XR) substantially reduces GI side effects and improves adherence. Long-term: vitamin B12 deficiency (10 to 30% of long-term users — check annually). Metformin does not cause hypoglycemia on its own.
Does metformin improve fertility in PCOS?: Yes, with Grade B evidence. Metformin improves ovulation rate and can restore regular cycles in women with PCOS and insulin resistance. Used alone or in combination with clomiphene citrate, it improves pregnancy rates. ESHRE 2023 recommends metformin as an adjunct to ovulation induction. However, evidence is insufficient to recommend it universally in all women with PCOS seeking conception, particularly in the absence of documented insulin resistance.
Should metformin be stopped during pregnancy with PCOS?: Current practice varies. Available data (including the MiG trial — Metformin in Gestational Diabetes) do not show increased congenital malformations at therapeutic doses. However, metformin crosses the placenta and long-term data on children exposed in utero remain limited. The general approach in the US is to discontinue metformin in the first trimester unless gestational diabetes or type 2 diabetes requires its continuation. Always discuss with your OB or endocrinologist before making any change during pregnancy.

Sources

How this page was written: See our editorial methodology →